AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) insider Lawrence G. Hamel sold 10,161 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $5.29, for a total value of $53,751.69. Following the transaction, the insider now directly owns 16,379 shares in the company, valued at $86,644.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of AcelRx Pharmaceuticals, Inc. (ACRX) opened at 5.50 on Wednesday. The company’s market cap is $249.59 million. AcelRx Pharmaceuticals, Inc. has a 1-year low of $1.95 and a 1-year high of $5.75. The stock has a 50 day moving average price of $3.44 and a 200-day moving average price of $2.88.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.01). The company had revenue of $2.66 million during the quarter, compared to analyst estimates of $2.63 million. Analysts predict that AcelRx Pharmaceuticals, Inc. will post ($1.13) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “AcelRx Pharmaceuticals, Inc. (ACRX) Insider Lawrence G. Hamel Sells 10,161 Shares of Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/04/acelrx-pharmaceuticals-inc-acrx-insider-lawrence-g-hamel-sells-10161-shares-of-stock.html.

A number of hedge funds have recently bought and sold shares of the business. LMR Partners LLP acquired a new stake in shares of AcelRx Pharmaceuticals during the second quarter worth $319,000. Teachers Advisors LLC boosted its position in shares of AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after acquiring an additional 8,475 shares during the period. WealthTrust Axiom LLC boosted its position in shares of AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after acquiring an additional 70,000 shares during the period. Bank of New York Mellon Corp boosted its position in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after acquiring an additional 6,942 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in shares of AcelRx Pharmaceuticals in the second quarter valued at about $530,000. Hedge funds and other institutional investors own 23.32% of the company’s stock.

ACRX has been the topic of a number of recent analyst reports. Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 1st. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Roth Capital reissued a “buy” rating and set a $12.50 target price on shares of AcelRx Pharmaceuticals in a research note on Thursday, August 10th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $7.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.93.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.